Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study

Completed · Phase 2

Conditions studied: Endometriosis

In brief

The proposed pilot study will estimate the efficacy and safety of a novel therapeutic agent, cabergoline, with a clinical standard therapy, norethindrone acetate, for the treatment of endometriosis-associated pain in young women with endometriosis.

Key facts

Study ID

NCT02542410

Run by

Boston Children's Hospital

People needed

10

Starts

2016-05-01

Expected to finish

2018-09-01

Last updated by the study team

2020-02-05

Who can join

Age: 15 and older, up to 40. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Surgically confirmed endometriosis
• Age between 15-40 y, and premenopausal
• Pelvic pain score ≥3 on a Visual Analog Scaleover the last month

You may not qualify if…

• Use of other concurrent hormone medications (such as birth control pills)
• Impaired liver function (ALT > 2x normal) or liver disease (cirrhosis, hepatitis)
• Pregnancy
• Breast cancer
• Active thromboembolic disease
• Uncontrolled hypertension, history of cardiac valve disorder, history of fibrotic disorders

Where it is running

• Children's Hospital Boston — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.